达拉菲尼加曲美替尼治疗非选择性晚期BRAF V600突变黑色素瘤：一项非干预、多中心、前瞻性试验。

IF 1.5 4区医学 Q3 DERMATOLOGY

Melanoma Research Pub Date : 2023-12-13 DOI:10.1097/cmr.0000000000000948

Erika Richtig, Van A Nguyen, Peter Koelblinger, Ingrid Wolf, Helmut Kehrer, Werner Saxinger, Julia M Ressler, Georg Weinlich, Damian Meyersburg, Christine Hafner, Elisabeth Jecel-Grill, Julian Kofler, Bernhard Lange-Asschenfeldt, Felix Weihsengruber, Klemens Rappersberger, Nina Svastics, Klaus Gasser, Arno Seeber, Franz Kratochvill, Sophie Nagler, Bernhard Mraz, Christoph Hoeller

{"title":"达拉菲尼加曲美替尼治疗非选择性晚期BRAF V600突变黑色素瘤：一项非干预、多中心、前瞻性试验。","authors":"Erika Richtig, Van A Nguyen, Peter Koelblinger, Ingrid Wolf, Helmut Kehrer, Werner Saxinger, Julia M Ressler, Georg Weinlich, Damian Meyersburg, Christine Hafner, Elisabeth Jecel-Grill, Julian Kofler, Bernhard Lange-Asschenfeldt, Felix Weihsengruber, Klemens Rappersberger, Nina Svastics, Klaus Gasser, Arno Seeber, Franz Kratochvill, Sophie Nagler, Bernhard Mraz, Christoph Hoeller","doi":"10.1097/cmr.0000000000000948","DOIUrl":null,"url":null,"abstract":"The efficacy of combined BRAF and MEK inhibition for BRAF V600-mutant melanoma in a broad patient population, including subgroups excluded from phase 3 trials, remains unanswered. This noninterventional study (DATUM-NIS) assessed the real-world efficacy, safety and tolerability of dabrafenib plus trametinib in Austrian patients with unresectable/metastatic melanoma.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.\",\"authors\":\"Erika Richtig, Van A Nguyen, Peter Koelblinger, Ingrid Wolf, Helmut Kehrer, Werner Saxinger, Julia M Ressler, Georg Weinlich, Damian Meyersburg, Christine Hafner, Elisabeth Jecel-Grill, Julian Kofler, Bernhard Lange-Asschenfeldt, Felix Weihsengruber, Klemens Rappersberger, Nina Svastics, Klaus Gasser, Arno Seeber, Franz Kratochvill, Sophie Nagler, Bernhard Mraz, Christoph Hoeller\",\"doi\":\"10.1097/cmr.0000000000000948\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The efficacy of combined BRAF and MEK inhibition for BRAF V600-mutant melanoma in a broad patient population, including subgroups excluded from phase 3 trials, remains unanswered. This noninterventional study (DATUM-NIS) assessed the real-world efficacy, safety and tolerability of dabrafenib plus trametinib in Austrian patients with unresectable/metastatic melanoma.\",\"PeriodicalId\":18550,\"journal\":{\"name\":\"Melanoma Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Melanoma Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/cmr.0000000000000948\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/cmr.0000000000000948","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在广泛的患者群体中，包括被排除在三期试验之外的亚组，联合抑制BRAF和MEK对BRAF V600突变黑色素瘤的疗效仍然没有答案。这项非常规研究（DATUM-NIS）评估了达拉非尼加曲美替尼治疗奥地利不可切除/转移性黑色素瘤患者的实际疗效、安全性和耐受性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.

The efficacy of combined BRAF and MEK inhibition for BRAF V600-mutant melanoma in a broad patient population, including subgroups excluded from phase 3 trials, remains unanswered. This noninterventional study (DATUM-NIS) assessed the real-world efficacy, safety and tolerability of dabrafenib plus trametinib in Austrian patients with unresectable/metastatic melanoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Melanoma Research 医学-皮肤病学

CiteScore

3.40

自引率

4.50%

发文量

139

审稿时长

6-12 weeks

期刊介绍： Melanoma Research is a well established international forum for the dissemination of new findings relating to melanoma. The aim of the Journal is to promote the level of informational exchange between those engaged in the field. Melanoma Research aims to encourage an informed and balanced view of experimental and clinical research and extend and stimulate communication and exchange of knowledge between investigators with differing areas of expertise. This will foster the development of translational research. The reporting of new clinical results and the effect and toxicity of new therapeutic agents and immunotherapy will be given emphasis by rapid publication of Short Communications. Thus, Melanoma Research seeks to present a coherent and up-to-date account of all aspects of investigations pertinent to melanoma. Consequently the scope of the Journal is broad, embracing the entire range of studies from fundamental and applied research in such subject areas as genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, immunology, and advances in clinical oncology influencing the prevention, diagnosis and treatment of melanoma.